141 related articles for article (PubMed ID: 33710645)
21. Long non-coding TUG1 accelerates prostate cancer progression through regulating miR-128-3p/YES1 axis.
Hao SD; Ma JX; Liu Y; Liu PJ; Qin Y
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):619-632. PubMed ID: 32016963
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
23. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
Kong Q; Chen XS; Tian T; Xia XY; Xu P
Oncol Rep; 2017 Feb; 37(2):803-812. PubMed ID: 27959429
[TBL] [Abstract][Full Text] [Related]
25. Oncogene miR-106a promotes proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
Luo B; Kang N; Chen Y; Liu L; Zhang Y
Minerva Med; 2018 Feb; 109(1):24-30. PubMed ID: 28889725
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1.
Wang M; Yu W; Gao J; Ma W; Frentsch M; Thiel A; Liu M; Rahman N; Qin Z; Li X
J Cell Physiol; 2020 Feb; 235(2):1588-1600. PubMed ID: 31309555
[TBL] [Abstract][Full Text] [Related]
28. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
30. TUG1 knockdown inhibits the tumorigenesis and progression of prostate cancer by regulating microRNA-496/Wnt/β-catenin pathway.
Li G; Yang J; Chong T; Huang Y; Liu Y; Li H
Anticancer Drugs; 2020 Jul; 31(6):592-600. PubMed ID: 32427740
[TBL] [Abstract][Full Text] [Related]
31. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
32. SP1-mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5.
Wang ZY; Duan Y; Wang P
J Cell Physiol; 2020 Apr; 235(4):3916-3927. PubMed ID: 31608997
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
34. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
35. miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.
Liu C; Guan H; Wang Y; Chen M; Xu B; Zhang L; Lu K; Tao T; Zhang X; Huang Y
PLoS One; 2015; 10(12):e0144073. PubMed ID: 26650737
[TBL] [Abstract][Full Text] [Related]
36. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
37. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
38. Long Noncoding RNA SOX2-OT Knockdown Inhibits Proliferation and Metastasis of Prostate Cancer Cells Through Modulating the miR-452-5p/HMGB3 Axis and Inactivating Wnt/β-Catenin Pathway.
Song X; Wang H; Wu J; Sun Y
Cancer Biother Radiopharm; 2020 Nov; 35(9):682-695. PubMed ID: 32407168
[No Abstract] [Full Text] [Related]
39. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
Wang W; Yang X; Dai J; Lu Y; Zhang J; Keller ET
Oncogene; 2019 Jun; 38(23):4540-4559. PubMed ID: 30755731
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
